Abcam, ab156876, Anti-Glutaminase antibody [EP7212]

Size: 100µL / 1mL
Anti-Glutaminase antibody [EP7212] (ab156876) is a rabbit monoclonal antibody detecting Glutaminase in Western Blot . Suitable for Human . - KO validated for confirmed specificity - Biophysical QC for unrivalled batch-batch consistency - Over 90 publications
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP7212,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-Glutaminase antibody [EP7212] (ab156876) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB) in Human samples.
What is the molecular weight of Glutaminase?
Anti-Glutaminase [EP7212] (ab156876) specifically detects a band for Glutaminase (UniProt: O94925) at a molecular weight of 73kDa.
Trusted by the scientific community
Anti-Glutaminase [EP7212] (ab156876) was first used in a scientific publication in 2013 and has been cited over 90 times in peer-reviewed journals.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Specificity confirmed
The specificity of Anti-Glutaminase antibody [EP7212] (ab156876) has been confirmed by Western blot testing in GLS Knockout HAP1 cells.
Other related products
We have a range of other formats of antibody clone [EP7212] also available for your convenience: ab156876, HRP -
ab200408
, Carrier free -
ab214802
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Glutaminase also known as GLS or GLS1 is an enzyme that catalyzes the conversion of glutamine to glutamate an important step in cellular nitrogen and energy metabolism. This enzyme weighs approximately 65 kDa and is expressed in various tissues particularly in the brain kidney and liver. Glutaminase exists in two isoforms GLS1 and GLS2 with GLS1 being the more studied due to its role in cancer metabolism.
Biological function summary
Glutaminase plays a central role in cellular processes by facilitating the production of glutamate which is an important neurotransmitter in the brain and a precursor for the synthesis of gamma-aminobutyric acid (GABA). It is not part of a larger complex but acts independently in the mitochondrial matrix where it performs the glutaminase reaction. The activity of this enzyme is monitored closely because it affects multiple cellular functions and has implications in many diseases.
Pathways
Glutaminase is instrumental in the glutaminolysis and tricarboxylic acid (TCA) cycles. These pathways are essential for cellular energy production and biosynthesis. GLS1 activity influences other proteins such as alanine transaminase (ALT) and aspartate transaminase (AST) which also play roles in amino acid metabolism and energy production. Glutaminase inhibitors have been explored as potential therapeutic agents by disrupting the glutaminolysis pathway in cancer cells leading to decreased tumor growth.
Glutaminase has a significant link to cancer and neurodegenerative diseases. In cancer GLS1 activity is often upregulated as tumor cells require increased glutamine metabolism for growth and survival making GLS1 inhibitors a target in cancer therapy. Neurodegenerative disorders such as Alzheimer's disease also show altered glutamate levels implicating glutaminase in disease progression. These disorders highlight the enzyme's potential connections with proteins like NMDA receptors in the brain where glutamate acts as a neurotransmitter affecting synaptic activity.